Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL
NCT04965493Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Sep 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-Free Survival up to 5 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04965493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965493.